Dr. Alan Wu is a true international eminence in the field of Toxicology and Clinical Chemistry. His research has earned him numerous awards and, specifically, he has been recognized as one of the 10 most important people in the world of In Vitro Diagnostic technology (IVD Industry). He also holds the Seligson-Golden Award and has received an award for Outstanding Contributions from the American Association of Clinical Chemistry. He has also been nominated for the Charles C. Shepard Award for Science, Laboratory and Methods (CDC/ATSDR).

This outstanding expert has been closely linked to the Laboratory of Toxicology and Clinical Chemistry of the San Francisco General Hospital, United States, where he has been its director. In this renowned institution he has developed some of his most important studies, among them, his approaches to cardiac biomarkers and point-of-care testing. In addition, he is responsible for the supervision of the staff, the approval of all tests and instruments used in this center and for ensuring compliance with the standards established by the regulatory agencies.

Dr. Wu also maintains a continuous commitment to the dissemination of scientific discoveries and contributions derived from his research. He has authored more than 500 peer-reviewed articles published in leading journals. He has also written 8 pocket books consisting of short stories designed to promote the value of the clinical laboratory to the general public.

As for his academic background, he received his PhD in Analytical Chemistry and completed a postdoctoral fellowship in Clinical Chemistry at Hartford Hospital. He is also certified by the American Board of Clinical Chemistry and is listed as a State Advisor on environmental biomonitoring and chemical-biological terrorism.

• Director of Toxicology and Clinical Chemistry, San Francisco General Hospital, United States
• Head of the Clinical Pharmacogenomics Laboratory at the University of California San Francisco (UCSF)
• Professor of Laboratory Medicine at UCSF 
• Director of the Neonatal Screening Program at the Department of Public Health in Richmond 
• Former Director of Clinical Pathology in the Department of Pathology and Laboratory Medicine at Hartford Hospital 
• Medical Advisor to the California State Poison Control Center 
• State Advisor to the Environmental Biomonitoring Committee and the Terrorism Preparedness Committee 
• Advisor to the Clinical Laboratory Standards Institute, Subcommittee on Establishment of Molecular Methods in Clinical Laboratory Settings 
• Editor-in-Chief of the journal Frontiers in Laboratory Medicine 
• Bachelor of Science in Chemistry and Biology from Purdue University 
• Ph.D. in Analytical Chemistry from the University of Illinois 
• Postdoctoral Fellow in Clinical Chemistry at Hartford Hospital
• Member of:
  
  • American Association for Clinical Chemistry
  • International Warfarin Pharmacogenetics Group Warfarin Consortium
  • International Tamoxifen Pharmacogenetics Consortium
  • College of American Pathologists, Division of Toxicology Resources